Eur Rev Med Pharmacol Sci 2017; 21 (7): 1583-1587

SUMOylation in cardiac disorders – a review

X.-C. Li, Y. Zeng, R.-R. Sun, M. Liu, S. Chen, P.-Y. Zhang

The Affiliated XuZhou Center Hospital of Nanjing University of Chinese Medicine, XuZhou Central Hospital, XuZhou, China. zpying58@126.com

SUMOylation regulates diverse cellular processes including transcription, cell cycle, protein stability, and apoptosis. A recent research has now revealed the role of SUMO1 in cardiac disorders. Studies have evidenced that failing heart induces SUMO2/3 conjugation. Moreover, increased SUMO2/3- dependent modification has been observed to result in congestive heart disease such as cardiac hypertrophy by promoting cardiac cell death. Also, few recent studies have confirmed the role of SUMOylation in cardiac protein degradation. On the other hand, over-expression of SENP5, SUMO2/3-specific deconjugation enzyme has been observed to result in dilated cardiomyopathy or cardiac failure. So, the present review article would enlighten the latest updates about SUMOylation and associated factors during cardiac disorders.

Free PDF Download

To cite this article

X.-C. Li, Y. Zeng, R.-R. Sun, M. Liu, S. Chen, P.-Y. Zhang
SUMOylation in cardiac disorders – a review

Eur Rev Med Pharmacol Sci
Year: 2017
Vol. 21 - N. 7
Pages: 1583-1587

Keywords Related articles:

  1. The SUMO-specific protease SENP5 controls DNA damage response and promotes tumorigenesis in hepatocellular carcinoma
  2. LncRNA MIAT enhances cardiac hypertrophy partly through sponging miR-150
  3. Atorvastatin improves cardiac function of rats with chronic cardiac failure via inhibiting Rac1/P47phox/P67phox-mediated ROS release
  4. Impact of epigenetics in the management of cardiovascular disease: a review
  5. Increase in G protein-coupled receptor autoantibodies with decline of cardiac function in hypercholesterolemic rats